BALTIMORE, Sept. 16 /PRNewswire/ -- Profectus BioSciences Inc., a biotechnology company that develops therapeutic and preventative technologies to reduce the morbidity and mortality of viral diseases, today announced the appointment of Dr. William Haseltine, PhD, to the company’s board of directors. A seasoned expert in innovating life saving drugs and medical devices, Haseltine brings more than thirty years of expertise in science and business development.
Dr. Haseltine currently serves as president of the Haseltine Foundation for Medical Sciences and the Arts, a foundation that supports access to high quality health for the poor and middle class of developing countries. He is also the chairman of Haseltine Global Health, LLC, a company dedicated to developing life saving drugs and medical devices.
In addition to these positions, he serves as an advisor to CMEA, a venture capital company, the Reliance Innovation Council, India and to several other biotechnology and pharmaceutical companies. Collectively, Dr. Haseltine has founded nine successful biotechnology companies including Human Genome Sciences, Inc.
“Dr. Haseltine is one of the industry’s most respected and talented individuals. His addition to our company is a tremendous testament to the things we are looking to accomplish as we proceed with the commercialization phase of our operations, and becoming the leading viral disease company,” said Shawn Patrick O’Brien, president and CEO of Profectus BioSciences. “Dr. Haseltine will provide strategic insight in helping us enhance and expand our technologies.”
Dr. Haseltine also has contributed to the academic community and is well known for his pioneering research on cancer, HIV/AIDS and genomics. As a professor at Harvard Medical School, he was founder and the chair of two academic research departments. Today, he is an adjunct professor at The Scripps Institute for Medical Research and the Institute of Chemical Engineering the University of Mumbai, India. He is chairman of the Board of the Berkeley Center for Synthetic Biology. Dr. Haseltine has published more than 200 manuscripts in peer reviewed journals and is the author of several books.
“This is a very exciting time for Profectus BioSciences,” said Dr. Haseltine. “With its seasoned leadership and innovative technologies, the company is perfectly positioned to help improve those who are afflicted with viral diseases. I’m very enthused to be a part of an organization that has the resources and expertise to realize this incredible opportunity.”
Aside from his professional expertise, Dr. Haseltine is also very active in public service. He is co-chair of the President’s Council of the Cold Spring Harbor Laboratory, a member of the Advisory Board of the Global Coalition on HIV/AIDS and he is a governor of the New York Academy of Science. He is a member of the Executive Committee of the Brookings Institution, a member of the Council on Foreign Relations, and a member of the Chairman’s Circle of the Asia Society. He is also a founder of the American Freedom Campaign.
About Profectus BioSciences Inc.
Profectus BioSciences Inc. began operations in early 2005 to develop and commercialize technologies to reduce the morbidity and mortality caused by human viral diseases, including the human immunodeficiency virus (HIV), the causative agent of AIDS. Founded to fulfill the mission of its co-founders Drs. Gallo, Blattner, and Redfield (collectively, the founders) for “bench-top-to-bedside” medicine, the Company applies its specific scientific expertise to help commercialize promising unique technologies used for human and animal health. For more information please visit: www.profectusbiosciences.com.
CONTACT: Jeff Meshulam of Profectus BioSciences, +1-443-543-5010,
meshulam@profectusbiosciences.com; or Christian Barbato of Garfield Group
Public Relations for Profectus BioSciences Inc., +1-215-867-8600 ext. 227,
cbarbato@garfieldgroup.com
Web site: http://www.profectusbiosciences.com/
